首页> 外文期刊>Rural and Remote Health >Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007-2012
【24h】

Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007-2012

机译:硝唑尼特治疗澳大利亚北领地的传染性腹泻2007-2012

获取原文
       

摘要

Introduction: Australian Indigenous children suffer a high burden of diarrhoeal disease. Nitazoxanide is an antimicrobial that has been shown to be effective against a broad range of enteropathogens. To date, its use has not been reported in the tropical Top End (northernmost part) of the Northern Territory, Australia. The objective was to describe the use of nitazoxanide at the Royal Darwin Hospital, Northern Territory, and to assess any association with the time to resolution of diarrhoea.Methods:Eligible children (≤13?years) were identified from dispensary records as having been prescribed nitazoxanide during the audit period, 1 July 2007 to 31?March 2012. Patient demographics, symptoms, diarrheal aetiology, treatment details and clinical outcomes were obtained by chart review. Results:Twenty-eight children were treated with nitazoxanide, mostly for Cryptosporidium infection associated with prolonged diarrhoea. Dehydration was evident in 27?(96%) children on admission, and 11?(41%) were underweight. Diarrhoeal duration prior to treatment was 11.5?days?(6.5?days pre- and 5?days post-admission). For children ≥12?months, nitazoxanide was prescribed according to guidelines stipulated by the Centers for Disease Control and Prevention (CDC). Resolution of diarrhoea occurred a median of 2.4?days (IQR:?1.4-7.3) after starting treatment. An increase in weight for length at discharge was found for all children. Conclusions:Prompt resolution of diarrhoea without adverse outcomes suggests nitazoxanide may be an effective treatment for Cryptosporidium infection in this setting. Its role in the treatment of other causes of infectious diarrhoea needs further investigation. Randomised trials will further direct its use and determine optimal dosing regimens.
机译:简介:澳大利亚土著儿童腹泻病负担高。 Nitazoxanide是一种抗菌剂,已被证明对多种肠道病原体有效。迄今为止,尚未在澳大利亚北领地的热带顶端(最北端)报告其使用情况。目的:描述硝唑尼特在北领地皇家达尔文医院的使用情况,并评估与解决腹泻时间的关系。方法:从药房记录中确定符合条件的儿童(≤13岁)在2007年7月1日至2012年3月31日期间的审核期间使用nitazoxanide。通过图表回顾获得患者的人口统计学,症状,腹泻病因,治疗细节和临床结局。结果:28例儿童接受了硝唑尼特治疗,主要是因为隐孢子虫感染引起的腹泻时间延长。入院时有27?(96%)儿童明显脱水,而11?(41%)体重不足。治疗前腹泻持续时间为11.5天(入院前6.5天和入院后5天)。对于≥12个月的儿童,根据疾病控制与预防中心(CDC)规定的指南开具硝唑尼特。开始治疗后,腹泻缓解的中位数为2.4天(IQR:1.4-7.3)。发现所有儿童出院时体重增加。结论:腹泻迅速解决而无不良后果提示硝唑尼特可能是这种情况下隐孢子虫感染的有效治疗方法。它在治疗感染性腹泻的其他原因中的作用有待进一步研究。随机试验将进一步指导其使用并确定最佳给药方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号